Armstrong AJ - Search Results

1

Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.

Bitting RL, Armstrong AJ. Bitting RL, et al. Among authors: armstrong aj. Endocr Relat Cancer. 2013 May 20;20(3):R83-99. doi: 10.1530/ERC-12-0394. Print 2013 Jun. Endocr Relat Cancer. 2013. PMID: 23456430 Review.

2

Cell signaling modifiers in prostate cancer.

Chen FL, Armstrong AJ, George DJ. Chen FL, et al. Among authors: armstrong aj. Cancer J. 2008 Jan-Feb;14(1):40-5. doi: 10.1097/PPO.0b013e318161d40f. Cancer J. 2008. PMID: 18303482 Review.

3

New drug development in metastatic prostate cancer.

Armstrong AJ, George DJ. Armstrong AJ, et al. Urol Oncol. 2008 Jul-Aug;26(4):430-7. doi: 10.1016/j.urolonc.2007.11.006. Urol Oncol. 2008. PMID: 18593623 Review.

4

A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.

Armstrong AJ, Creel P, Turnbull J, Moore C, Jaffe TA, Haley S, Petros W, Yenser S, Gockerman JP, Sleep D, Hurwitz H, George DJ. Armstrong AJ, et al. Clin Cancer Res. 2008 Oct 1;14(19):6270-6. doi: 10.1158/1078-0432.CCR-08-1085. Clin Cancer Res. 2008. PMID: 18829508 Clinical Trial.

5

Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.

Armstrong AJ, Febbo PG. Armstrong AJ, et al. Oncologist. 2009 Aug;14(8):816-27. doi: 10.1634/theoncologist.2009-0043. Epub 2009 Aug 14. Oncologist. 2009. PMID: 19684076 Free article. Review.

6

The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.

Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S. Armstrong AJ, et al. Eur J Cancer. 2010 Feb;46(3):517-25. doi: 10.1016/j.ejca.2009.11.007. Epub 2009 Dec 11. Eur J Cancer. 2010. PMID: 20005697 Clinical Trial.

7

Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.

Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M. Armstrong AJ, et al. Clin Cancer Res. 2010 Jan 1;16(1):203-11. doi: 10.1158/1078-0432.CCR-09-2514. Epub 2009 Dec 15. Clin Cancer Res. 2010. PMID: 20008841

8

A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.

Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, Mundy K, Davis SL, Wang T, Albadine R, Schultz L, Partin AW, Jimeno A, Fedor H, Febbo PG, George DJ, Gurganus R, De Marzo AM, Carducci MA. Armstrong AJ, et al. Clin Cancer Res. 2010 Jun 1;16(11):3057-66. doi: 10.1158/1078-0432.CCR-10-0124. Epub 2010 May 25. Clin Cancer Res. 2010. PMID: 20501622 Free PMC article. Clinical Trial.

9

The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.

Sonpavde G, Pond GR, Berry WR, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ. Sonpavde G, et al. Among authors: armstrong aj. Cancer. 2011 Sep 1;117(17):3963-71. doi: 10.1002/cncr.25982. Epub 2011 Mar 1. Cancer. 2011. PMID: 21365623 Free PMC article.

10

A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.

Whang YE, Armstrong AJ, Rathmell WK, Godley PA, Kim WY, Pruthi RS, Wallen EM, Crane JM, Moore DT, Grigson G, Morris K, Watkins CP, George DJ. Whang YE, et al. Among authors: armstrong aj. Urol Oncol. 2013 Jan;31(1):82-6. doi: 10.1016/j.urolonc.2010.09.018. Epub 2011 Mar 10. Urol Oncol. 2013. PMID: 21396844 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

388 results

Search Page

Filters